m+Medelevator.RU
← Поиск публикаций
Journal of Alzheimer's disease : JAD · 2025

Application of machine learning reveals diagnostic biomarkers related to pyroptosis in Alzheimer's disease and analysis of immune infiltration.

СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Huang Yujuan, Xu Tu, Wang Li, Xiang Ruping, Zhou Meijun, Yu Huiyun, Liu Dong, Chen Zhicheng

Аннотация

BackgroundAlzheimer's disease (AD) is characterized by complex pathological mechanisms, with pyroptosis potentially contributing to neuroinflammation.ObjectiveTo identify pyroptosis-related genes (PRGs) in AD and explore their role in neuroinflammation, aiming to provide potential biomarkers and therapeutic targets for precision medicine in AD treatment.MethodsTranscriptomic data from AD brain tissues (GEO database) were analyzed using multi-omics integration and machine learning. Key PRGs were screened via weighted gene co-expression network analysis (WGCNA), LASSO regression, random forest, and SVM-RFE algorithms. Molecular subtypes and therapeutic potential were assessed through unsupervised clustering and molecular docking.ResultsAnalysis identified 609 differentially expressed genes (DEGs), with upregulated genes enriched in DNA transcription and mitosis-related pathways. Six core PRGs (MIB1, TUG1, GATA1, CA1, CFH, IL17A) demonstrated strong diagnostic accuracy (AUC > 0.85). Unsupervised clustering revealed two AD subtypes: a high-risk subtype with activated pyroptosis-inflammatory pathways and distinct immune microenvironment features (p < 0.05). Molecular docking confirmed stable binding between CFH and the anti-AD drug candidate fludrocortisone (binding energy < -7 kcal/mol).ConclusionsPyroptosis modulates neuroinflammation to drive AD progression. CFH and other PRGs serve as promising biomarkers and therapeutic targets, advancing precision strategies for AD subtyping and intervention.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты